Drugs / CH505 TF mRNA-gp160
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06557785 | Nov 2024 → Mar 2027 expected | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CH505 TF mRNA-gp160 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06557785 ↗ |
| Modality | Messenger RNA (mRNA) | “Both products are mRNA encapsulated in lipid nanoparticles (LNPs)” NCT06557785 ↗ |
| Route | Intramuscular | “To be administered intramuscularly as a split dose” NCT06557785 ↗ |